ADMANGMHealthcare·Biotechnology#87 in industry

ADMA Biologics, Inc.

Reports in 9d· 2026-05-06

-34.1% · 90d

$10.93

-0.33 (-2.93%)

After-Hours $11.10(+0.17)

News

No News Yet

Press releases and SEC filings for ADMA will appear here as they are published.

Check back later for updates

Key Data

Market Cap$2.54B

Open$11.25

Prev Close$11.26

Day Range$10.91 – $11.33

52W Range$7.21 – $25.67

Volume4,019,269

P/E (TTM)18.22

EPS$0.60

Dividend Yield—

Beta0.82

Profit Margin28.80%

Revenue Growth15.90%

Price Target$20.67(+89.1%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Strong Buy4 analysts

Buy 3Hold 1Sell 0

About

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Healthcare · Biotechnology

640 employees

www.admabiologics.com